Effectiveness and Tolerability of Eptinezumab
CompletedNCT06409845
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Study details
- Official title
- Effectiveness and Tolerability of Eptinezumab: a Prospective, Multicentric, Cohort Study
- Conditions
- Migraine
- Migraine With Aura
- Migraine Without Aura
- Chronic Migraine
- Interventions
- Drug: Eptinezumab 100 or 300 mg ev
- Sponsor
- University of Florence
- Collaborators
- Azienda Ospedaliero Universitaria Policlinico Modena; Società Italiana per lo Studio delle Cefalee; IRCCS National Neurological Institute "C. Mondino" Foundation; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari; Università degli Studi dell'Aquila; University of Roma La Sapienza; Euganea Health Unit, Padua, Italy; Azienda Ospedaliero-Universitaria di Parma; Azienda Ospedaliera S. Maria della Misericordia; A.O.U. Città della Salute e della Scienza; Cliniche Humanitas Gavazzeni; University of Campania Luigi Vanvitelli; Ospedale Santo Stefano; Azienda Policlinico Umberto I; Auxologico San Luca; Asst Degli Spedali Civili Di Brescia; Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Start date
- 2024-03-26
- Primary completion
- 2025-04-01
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Italy
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III); * Good compliance to study procedures; * Availability of headache diary at least of the preceding months before enrolment; * At least 8 monthly migraine days. Exclusion Criteria: * Subjects with contraindications for use of eptinezumab; * Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments; * medical comorbidities that could interfere with study results; * Pregnancy and breastfeeding * Changes in preventive treatments in the month before the first administration of eptinezumab
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06409845